CN102460173A - 组蛋白修饰用于癌症的临床诊断和预后 - Google Patents

组蛋白修饰用于癌症的临床诊断和预后 Download PDF

Info

Publication number
CN102460173A
CN102460173A CN2010800251368A CN201080025136A CN102460173A CN 102460173 A CN102460173 A CN 102460173A CN 2010800251368 A CN2010800251368 A CN 2010800251368A CN 201080025136 A CN201080025136 A CN 201080025136A CN 102460173 A CN102460173 A CN 102460173A
Authority
CN
China
Prior art keywords
cancer
histone
h3k18ac
level
modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800251368A
Other languages
English (en)
Chinese (zh)
Inventor
D·W·道森
S·K·库尔迪斯坦尼
D·B·泽尔格森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN102460173A publication Critical patent/CN102460173A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2010800251368A 2009-04-14 2010-04-14 组蛋白修饰用于癌症的临床诊断和预后 Pending CN102460173A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16921609P 2009-04-14 2009-04-14
US16921209P 2009-04-14 2009-04-14
US61/169,216 2009-04-14
US61/169,212 2009-04-14
US22516209P 2009-07-13 2009-07-13
US61/225,162 2009-07-13
PCT/US2010/031112 WO2010120942A2 (en) 2009-04-14 2010-04-14 Histone modification patterns for clinical diagnosis and prognosis of cancer

Publications (1)

Publication Number Publication Date
CN102460173A true CN102460173A (zh) 2012-05-16

Family

ID=42983132

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800251368A Pending CN102460173A (zh) 2009-04-14 2010-04-14 组蛋白修饰用于癌症的临床诊断和预后

Country Status (8)

Country Link
US (1) US20120094949A1 (https=)
EP (1) EP2419737A4 (https=)
JP (1) JP2012524278A (https=)
CN (1) CN102460173A (https=)
AU (1) AU2010236415A1 (https=)
BR (1) BRPI1013546A2 (https=)
CA (1) CA2758933A1 (https=)
WO (1) WO2010120942A2 (https=)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106103739A (zh) * 2013-12-30 2016-11-09 新加坡科技研究局 用于测量胃肠癌中的生物标记物的方法
CN107209190A (zh) * 2014-10-29 2017-09-26 比利时意志有限责任公司 用于富集循环肿瘤dna的方法
CN108367995A (zh) * 2015-10-06 2018-08-03 安大略省癌症研究所 靶向组蛋白途径以检测和克服蒽环类抗生素耐受性
CN108957004A (zh) * 2018-07-09 2018-12-07 东南大学 检测H3K9me2和H3K36me3表达量的试剂在制备胃癌预后评估试剂盒中的应用
CN109564225A (zh) * 2016-08-09 2019-04-02 B.R.A.H.M.S 有限公司 作为指示不良事件的标志物的组蛋白和/或proADM
CN109791154A (zh) * 2016-07-25 2019-05-21 比利时意志有限责任公司 结肠直肠癌的组合测试
CN110221072A (zh) * 2019-06-10 2019-09-10 东南大学 检测H3K9甲基化和E-cadherin表达量试剂在制备肝癌预后评估试剂盒的应用
CN112904006A (zh) * 2021-01-28 2021-06-04 中山大学 一种乳腺癌预后预测分子标志物及其应用
WO2024077601A1 (en) * 2022-10-14 2024-04-18 Guangdong Tcrcure Biopharma Technology Co., Ltd. Peptide vaccines against glioma and uses thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
CN104067125B (zh) * 2011-12-07 2017-12-26 比利时意志有限责任公司 用于检测核小体加合物的方法
GB201303576D0 (en) * 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for predicting therapy efficacy using nucleosome structure biomarkers
GB201303575D0 (en) * 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for detecting histone modifications in nucleosomes
JP2016044993A (ja) * 2014-08-20 2016-04-04 有限会社マイテック ヒストン化学修飾判定による癌診断方法
US10639349B2 (en) 2015-04-06 2020-05-05 The Johns Hopkins University H3T3A mutant protein efficiently reduces H3T3P and causes increased cell death of rapidly dividing cells
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
WO2024233383A1 (en) * 2023-05-05 2024-11-14 University Of Utah Research Foundation Systems and methods for point-of-care assessment based on pathology image analysis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
ATE489624T1 (de) * 2005-04-29 2010-12-15 Univ California Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose
EP1937837A2 (en) * 2005-07-29 2008-07-02 Siemens Healthcare Diagnostics Inc. Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106103739A (zh) * 2013-12-30 2016-11-09 新加坡科技研究局 用于测量胃肠癌中的生物标记物的方法
CN107209190A (zh) * 2014-10-29 2017-09-26 比利时意志有限责任公司 用于富集循环肿瘤dna的方法
CN108367995A (zh) * 2015-10-06 2018-08-03 安大略省癌症研究所 靶向组蛋白途径以检测和克服蒽环类抗生素耐受性
CN108367995B (zh) * 2015-10-06 2021-08-27 安大略省癌症研究所 靶向组蛋白途径以检测和克服蒽环类抗生素耐受性
CN109791154A (zh) * 2016-07-25 2019-05-21 比利时意志有限责任公司 结肠直肠癌的组合测试
CN109564225A (zh) * 2016-08-09 2019-04-02 B.R.A.H.M.S 有限公司 作为指示不良事件的标志物的组蛋白和/或proADM
CN108957004A (zh) * 2018-07-09 2018-12-07 东南大学 检测H3K9me2和H3K36me3表达量的试剂在制备胃癌预后评估试剂盒中的应用
CN108957004B (zh) * 2018-07-09 2021-10-19 东南大学 检测H3K9me2和H3K36me3表达量的试剂在制备胃癌预后评估试剂盒中的应用
CN110221072A (zh) * 2019-06-10 2019-09-10 东南大学 检测H3K9甲基化和E-cadherin表达量试剂在制备肝癌预后评估试剂盒的应用
CN112904006A (zh) * 2021-01-28 2021-06-04 中山大学 一种乳腺癌预后预测分子标志物及其应用
WO2024077601A1 (en) * 2022-10-14 2024-04-18 Guangdong Tcrcure Biopharma Technology Co., Ltd. Peptide vaccines against glioma and uses thereof

Also Published As

Publication number Publication date
WO2010120942A2 (en) 2010-10-21
EP2419737A4 (en) 2013-02-13
JP2012524278A (ja) 2012-10-11
WO2010120942A3 (en) 2011-02-24
US20120094949A1 (en) 2012-04-19
CA2758933A1 (en) 2010-10-21
AU2010236415A1 (en) 2011-12-01
EP2419737A2 (en) 2012-02-22
BRPI1013546A2 (pt) 2019-04-09

Similar Documents

Publication Publication Date Title
CN102460173A (zh) 组蛋白修饰用于癌症的临床诊断和预后
Zeng et al. LncRNA-MTA2TR functions as a promoter in pancreatic cancer via driving deacetylation-dependent accumulation of HIF-1α
Anwar et al. p38-mediated phosphorylation at T367 induces EZH2 cytoplasmic localization to promote breast cancer metastasis
Stahl et al. Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer
Xu et al. Loss of polarity protein AF6 promotes pancreatic cancer metastasis by inducing Snail expression
Necela et al. Folate receptor-α (FOLR1) expression and function in triple negative tumors
Robinson et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing
US10253368B2 (en) Molecular signatures of ovarian cancer
Sun et al. C/EBP-β-activated microRNA-223 promotes tumour growth through targeting RASA1 in human colorectal cancer
Tang et al. LncRNA SLCO4A1-AS1 predicts poor prognosis and promotes proliferation and metastasis via the EGFR/MAPK pathway in colorectal cancer
Ouaissi et al. Further characterization of HDAC and SIRT gene expression patterns in pancreatic cancer and their relation to disease outcome
Chen et al. FSCN1 is an effective marker of poor prognosis and a potential therapeutic target in human tongue squamous cell carcinoma
Ouyang et al. COP1, the negative regulator of ETV1, influences prognosis in triple-negative breast cancer
Lin et al. Knockdown of OCT4 suppresses the growth and invasion of pancreatic cancer cells through inhibition of the AKT pathway
Lee et al. ESRP1-regulated isoform switching of LRRFIP2 determines metastasis of gastric cancer
Wang et al. Pharmacological inhibition of Bmi1 by PTC-209 impaired tumor growth in head neck squamous cell carcinoma
Xie et al. Decreased miR-320a promotes invasion and metastasis of tumor budding cells in tongue squamous cell carcinoma
Gao et al. CXCR4 as a novel predictive biomarker for metastasis and poor prognosis in colorectal cancer
Li et al. Overexpression of Annexin A2 promotes proliferation by forming a Glypican 1/c-Myc positive feedback loop: prognostic significance in human glioma
Shao et al. High-level SAE2 promotes malignant phenotype and predicts outcome in gastric cancer
CN102472753B (zh) 基于组蛋白macroH2A同工型预测癌症复发风险的诊断方法
Schlomm et al. Molecular staging of prostate cancer in the year 2007
Cecconi et al. Proteomics in pancreatic cancer research
Adamczyk et al. Expression of ER/PR/HER2, basal markers and adhesion molecules in primary breast cancer and in lymph nodes metastases: a comparative immunohistochemical analysis
Wu et al. Cytosolic Cadherin 4 promotes angiogenesis and metastasis in papillary thyroid cancer by suppressing the ubiquitination/degradation of β-catenin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120516